Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shire (SHPGY) recently announced that the US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) filed by Actavis for its generic version of Adderall XR. Adderall XR is indicated for attention-deficit/hyperactivity disorder (ADHD).
The FDA responded to a citizen petition filed by the company for Adderall XR. The FDA said that all the companies filing an ANDA should establish bioequivalence using partial area under the curve measurements for both d- and l- amphetamine at 5 hours and beyond. The citizen petition was filed by Shire in October 2005.
We note that, at present, Iceland-based Actavis is in the process of being acquired by Watson Pharmaceuticals Inc. (WPI).
Our Take
Adderall XR, with $111.4 million revenues in the first quarter of 2012, is one of the top revenue grossers at Shire. As per data provided by IMS Health National Prescription Audit, Adderall XR enjoys a 7% share of the US ADHD market.
Apart from this, the company has two authorized generic partners – Teva Pharmaceuticals (TEVA - Analyst Report) and Impax Laboratories (IPXL - Snapshot Report). We believe that the entry of additional generic versions of Adderall XR will eat into Adderall XR revenues.
Shire in engaged in several lawsuits for Adderall XR. On November 1, 2010, Impax filed a suit against Shire claiming a breach of contract regarding the supply of the generic version of Adderall XR. Shire has been supplying Impax with the generic version of the ADHD drug since October 2009. Shire has filed a counterclaim against Impax.
The company is also entangled in a legal battle with Watson Pharma, which is also seeking to market generic versions of the drug in multiple doses. In April 2011, Shire filed a patent infringement lawsuit and breach of contract against Watson Pharma following the ANDA filed by Watson with the FDA for its generic version of the drug.
We currently have a Neutral recommendation on Shire. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Get the full Snapshot Report on IPXL - FREE
Get the full Analyst Report on TEVA - FREE